Arthrosi Presents Positive Phase 2 Data for AR882 at the European Alliance of Associations for Rheumatology (EULAR) Congress 2024

— Continued treatment with AR882 demonstrated safe, efficacious and sustained reduction in sUA at 12 months — — AR882 achieved deep and durable tophus and crystal volume dissolution at 12 months — SAN DIEGO, June 14, 2024 /PRNewswire/ — Arthrosi Therapeutics, Inc., a late-stage…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks